Can GILD sustain its earnings growth momentum into 2025?

**Gilead Sciences (GILD) is poised to sustain its earnings growth momentum into 2025**, based on several key factors:

1. **Positive Earnings Outlook**: GILD's earnings per share (EPS) is forecasted to grow by 22.9% per annum. This indicates a strong upward trend in profitability that could continue into the upcoming year.
2. **Revenue Growth Projection**: The company's revenue is expected to grow by 3.3% per annum. While this is a more modest growth rate than the earnings, it still suggests a stable and positive revenue trajectory.
3. **Return on Equity (ROE) Forecast**: GILD's ROE is forecasted to be 31.2% in three years. A high ROE typically indicates efficient use of equity to generate profits, which is a favorable sign for future earnings growth.
4. **Analyst Coverage and Confidence**: Despite some recent fluctuations in stock price and market conditions, analyst coverage remains positive, with a "Buy" rating and a consensus EPS estimates that have not fallen significantly.
5. **Dividend Increase and Shareholder Returns**: GILD has recently increased its dividend to $0.79 per share, which could attract income-focused investors and reflect the company's confidence in its cash flow and future earnings.
6. **Innovation and Product Pipeline**: The company has been actively involved in research and development, including presentations at industry conferences and filings for new treatments. A strong product pipeline can provide a steady stream of new revenue opportunities.

In conclusion, GILD's solid financial outlook, positive analyst sentiment, and strategic initiatives suggest that the company is well-positioned to sustain its earnings growth momentum into 2025. However, investors should continue to monitor the company's performance closely, particularly in relation to its product pipeline and market conditions.